ALPHA TEKNOVA INC

NASDAQ: TKNO (Alpha Teknova, Inc.)

最近更新时间: 13 Nov, 12:03PM

8.11

-0.19 (-2.23%)

前收盘价格 8.30
成交量 80,977
平均成交量 (3个月) 436,782
市值 479,950,880
价格/销量 (P/S) 9.19
52周波幅
1.91 (-76%) — 9.48 (16%)
利润日期 4 Nov 2026
营业毛利率 -34.76%
营业利益率 (TTM) -31.56%
稀释每股收益 (EPS TTM) -0.300
季度收入增长率 (YOY) 21.50%
总债务/股东权益 (D/E MRQ) 45.14%
流动比率 (MRQ) 3.56
营业现金流 (OCF TTM) -5.57 M
杠杆自由现金流 (LFCF TTM) -2.06 M
资产报酬率 (ROA TTM) -8.96%
股东权益报酬率 (ROE TTM) -24.12%

AIStockmoo 评分

0.8
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
资本回报 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年呈上升趋势。股价略低于52周高点。 参考
上升趋势,但均线已走平。股价接近均线。上涨日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
持仓情绪 参考 NA
内部交易活动 参考 NA
机构资金流 参考 NA
空头持仓 参考 NA
市场环境偏谨慎。 参考
行业表现优于大市。
各支柱方向一致,评分因此加强。
每股盈利有升有降。近年曾亏损。 参考
近期出现看涨反转形态:看涨吞没。 参考
高于中期趋势线。 参考
股价高于其52周平均水平。5年来下跌。 参考
短期动能上升。 参考
股价处于支撑位与阻力位之间。 参考
最终评分 0.79
全部展开

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 混合的 混合的
Drug Manufacturers - Specialty & Generic (全球的) 混合的 混合的
股票 Alpha Teknova, Inc. 混合的 混合的

相关股票

股票 市值 DY P/E(TTM) P/B 评分
TKNO 480 M - - - 0.8
SUPN 6 B 27.84% - 1.59 -1.0
ANIP 2 B - 13.74 2.57 -0.1
COLL 783 M - 23.13 2.72 0.1
AQST 435 M - - - -1.7
TLRY 279 M - - 0.200 -2.2

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Value
内部持股比例 7.95%
机构持股比例 76.88%

该时间范围内无数据。

该时间范围内无数据。

5 正面 0 负面 1 中性
日期 类型 细节
05 Nov 2026 Yahoo Finance Alpha Teknova Inc (TKNO) (Q3 2026) Earnings Call Highlights: Record Revenue, Surging Clinical ...
Alpha Teknova Inc (TKNO) posted record Q3 2026 revenue of $12.2 million, up 22% year-over-year, as Clinical Solutions jumped 86% and gross margin expanded to 38.0%.
05 Nov 2026 Yahoo Finance Alpha Teknova (TKNO) Q3 2026 Earnings Call Transcript
Biopharma demand lifted results and a $46 million raise bolstered the balance sheet.
05 Nov 2026 Yahoo Finance Alpha Teknova Q3 Earnings Call Highlights
Alpha Teknova (NASDAQ:TKNO) raised its 2026 revenue guidance after reporting a second consecutive quarter of record revenue, as demand for custom products from biopharma, life science tools and diagnostics customers helped drive 22% year-over-year growth. The company now expects full-year revenue o…
04 Nov 2026 Yahoo Finance Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue Estimates
Alpha Teknova (TKNO) delivered earnings and revenue surprises of 0.00% and +8.58%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
04 Nov 2026 Yahoo Finance Alpha Teknova: Q3 Earnings Snapshot
(TKNO) on Wednesday reported a loss of $3.The Hollister, California-based company said it had a loss of 6 cents per share.
04 Nov 2026 Yahoo Finance Teknova Reports Third Quarter 2026 Financial Results
Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior yearCompany raises 2026 revenue guidance to $46-48 millionStrengthened balance sheet with $46 million public equity offering completed in October 2026 HOLLISTER, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alpha…
30 Oct 2026 Yahoo Finance Full-Year Revenue Guidance Hike Drove Alpha Teknova (TKNO) Higher
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. Conestoga Capital Advisors released its third-quarter 2026 investor letter, outlining a shifting macroeconomic backdrop for small-cap equities. After a strong…
23 Oct 2026 Yahoo Finance Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?
Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
21 Oct 2026 Yahoo Finance Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report…
20 Oct 2026 Yahoo Finance Teknova Announces Pricing of $40 Million Public Offering of Common Stock
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten…
20 Oct 2026 Yahoo Finance Alpha Teknova stock tumbles on public offering announcement
Investing.com -- Alpha Teknova Inc (NASDAQ:TKNO) shares fell 22.3% in after-hours trading Tuesday following the company's announcement of an underwritten public offering of its common stock.
20 Oct 2026 Yahoo Finance Teknova Announces Proposed Public Offering of Common Stock
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an…
20 Oct 2026 Yahoo Finance Teknova Announces Preliminary Third Quarter Financial Results
HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing…
02 Oct 2026 Yahoo Finance Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
Developers of advanced therapies using PluriFreeze during preclinical stages can seamlessly scale to clinical manufacturing and cross-reference the Drug Master File in FDA submissionsHOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx…
01 Oct 2026 Yahoo Finance All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy
Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
22 Sep 2026 Yahoo Finance Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?
Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
16 Sep 2026 Yahoo Finance Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling
Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround timeHOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha…
显示更多

近期信号 K线形态与EMA交叉

▲ 看涨吞没 短期 · 日线 · 2个交易日前 · 18 Nov
下跌后,阳线实体完全覆盖前一根阴线。看涨反转信号。

技术形态 中期

趋势排列
斜率
入场位置
成交量
上升趋势,但均线已走平。股价接近均线。上涨日成交量较大。
最近支撑: 7.36 – 7.99 · 强
最近阻力: 8.03 – 8.49 · 强

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

风险 / 回报
TP1:
TP2:

以入场价计算,止损的亏损相对每个目标价的盈利。通常追求 2 或以上的比率。

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票